Experts InSight

In today's episode, host Dr. Ben Young is joined by Dr. Stephen McLeod, Academy CEO, and Rebecca Hyder, Vice President of Governmental Affairs. The panel discusses why we have a National Eye Institute (NEI), how it was successfully preserved as an independent, stand-alone entity within the National Institutes of Health (NIH), and what threats to the institute remain on the horizon.
For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

In today's episode, host Dr. Amanda Redfern welcomes Dr. Madhura Tamhankar to discuss a new study using IRIS Registry and Komodo Health claims data that upends Rundle's 1940s biphasic model of thyroid eye disease (TED). Drawing on more than 34,000 patients with 5-year median follow-up, Dr. Tamhankar's study found that even among patients with initially mild disease, 1 in 3 progress within 5 years, with rates climbing from 12% at year 1 to 38% by year 8. Dr. Tamhankar reviews the study's methodology and its implications for patient care, including surgical timing, informed consent, and specialist referral.
For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Host Dr. Jay Sridhar welcomes Dr. Steven Gedde, the incoming CEO of the American Board of Ophthalmology (ABO), to discuss his outlook on medical education and the evolving board certification process. As medical knowledge now doubles approximately every 60 days, Dr. Gedde envisions the ABO shifting its focus from testing facts to assessing skills like communication, professionalism, and the use of technology. Although current surgical assessments focus on knowledge and decision-making, future evaluations may leverage AI and virtual reality to test technical competence. 
For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Host Dr. Jay Sridhar welcomes ophthalmology program directors Drs. Chris Alabiad and Alice Zhang to discuss the ophthalmology residency match, the rising pool of reapplicants to the field, and how to mentor and advise students pursuing reapplication.
For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Do the benefits really outweigh the risks when it comes to the use of thrombolytic drugs for central retinal artery occlusion (CRAO)? Drs. Amanda Henderson and Michael Carper weigh in on the recently published Tenecteplase in Central Retinal Artery Occlusion Study (TenCRAOS) and how ophthalmologists should proceed in their management of CRAO with tenecteplase (TNK) or another tissue plasminogen activator (tPA).
For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.